Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

Rhea-AI Summary

Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call on May 12, 2022, at 4:30 p.m. EDT to discuss its Q1 2022 financial results and provide a corporate update. The call can be accessed via phone or through a live audio webcast on the company's website. Trevi is focused on developing Haduvio™, an investigational therapy aimed at treating pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis. Haduvio has received Fast Track designation from the FDA for its proposed indication.

Positive

• Haduvio has received Fast Track designation from the FDA for pruritus treatment, which may expedite its development.
• Conference call scheduled for May 12 to discuss Q1 2022 financial results, indicating proactive communication with investors.

Negative

• None.

Conference Call and Webcast to be Held at 4:30 p.m. EDT

NEW HAVEN, Conn., May 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, May 12, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2022.

Trevi Therapeutics will host a conference call on May 12 to review Q1 2022 financial results

To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 5008663. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in adults with idiopathic pulmonary fibrosis (IPF). These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently classified as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Nalbuphine ER has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in adults with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q1-2022-financial-results-and-provide-a-corporate-update-on-may-12-2022-301541249.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When is Trevi Therapeutics' conference call regarding Q1 2022 financial results?

The conference call is scheduled for May 12, 2022, at 4:30 p.m. EDT.

What is Haduvio and its significance for Trevi Therapeutics?

Haduvio is an investigational therapy for pruritus and chronic cough, which has received Fast Track designation from the FDA.

What time is the Q1 2022 earnings call for TRVI?

The Q1 2022 earnings call for Trevi Therapeutics will take place at 4:30 p.m. EDT on May 12, 2022.

How can I access the Trevi Therapeutics conference call?

The conference call can be accessed via phone or through a live audio webcast on their website.

What are the main focuses of Trevi Therapeutics' clinical trials?

The main focuses are on Haduvio for treating pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis.